Amol A. Tatode

Dr. Amol A. Tatode

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
TPTanvi Dinesh Premchandani
Tanvi Dinesh Premchandani
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
MUMilind Janrao Umekar
Milind Janrao Umekar
MQMohammad Qutub
Mohammad Qutub
PSPriyanka Singanwad
Priyanka Singanwad
Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, and the ability to traverse physiological obstacles such as the blood–brain barrier (BBB) and dense tumor stroma. Recent advances in exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) and cargo loading (siRNA, CRISPR-Cas systems, and chemotherapeutics)—have enhanced their precision and therapeutic utility. For CNS delivery, exosomes functionalized with brain-homing peptides (e.g., RVG or TfR ligands) have enabled the efficient transport of neuroprotective agents or gene-editing tools to treat Alzheimer’s disease or glioblastoma. In oncology, engineered exosomes loaded with tumor-suppressive miRNAs or immune checkpoint inhibitors exploit tumor microenvironment (TME) features, such as acidity or enzyme overexpression, for spatially controlled drug release. Furthermore, hybrid exosome–liposome systems and exosome–biomaterial composites are being explored to improve payload capacity and stability. Despite progress, challenges persist in scalable production, batch consistency, and regulatory standardization. This review critically evaluates engineering strategies, preclinical success, and translational hurdles while proposing innovations such as AI-driven exosome design and patient-derived exosome platforms for personalized therapy. By bridging nanotechnology and biomedicine, engineered exosomes can represent a paradigm shift in targeted drug delivery, offering safer and more effective solutions for historically intractable diseases.

12 November 2024 in JCIS Open
Verified
Journal Article
Open access
MQMohammad Qutub
Mohammad Qutub
ATAmol A. Tatode
Amol A. Tatode
TPTanvi Premchandani
Tanvi Premchandani
JTJayshree Taksande
Jayshree Taksande
DMDadaso Mane
Dadaso Mane
MUMilind Umekar
Milind Umekar

16 May 2025 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MQMohammad Qutub
Mohammad Qutub
UHUjban Md Hussain
Ujban Md Hussain
ATAmol A. Tatode
Amol A. Tatode
TPTanvi Premchandani
Tanvi Premchandani
RKRahmuddin Khan
Rahmuddin Khan
PSPriyanka Singanwad
Priyanka Singanwad

31 January 2025 in Nano Trends
Verified
Journal Article
Open access
KPKajol Patil
Kajol Patil
PSPramod S. Salve
Pramod S. Salve
UHUjban Hussain
Ujban Hussain
ATAmol A. Tatode
Amol A. Tatode
MQMohammad Qutub
Mohammad Qutub

5 January 2025 in Aspects of Molecular Medicine
Verified
Journal Article
Open access
MQMohammad Qutub
Mohammad Qutub
ATAmol A. Tatode
Amol A. Tatode
JTJayshree Taksande
Jayshree Taksande
TPTanvi Premchandani
Tanvi Premchandani
MUMilind Umekar
Milind Umekar
DMDadaso Mane
Dadaso Mane

15 July 2025 in Neuropeptides
Verified
Journal Article
Closed access
PSPriyanka Singanwad
Priyanka Singanwad
ATAmol A. Tatode
Amol A. Tatode
MQMohammad Qutub
Mohammad Qutub
BTBrijesh Taksande
Brijesh Taksande
MUMilind Umekar
Milind Umekar
TPTanvi Premchandani
Tanvi Premchandani